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Stratification of mortality by risk scores from the EPHESUS trial
reveals significant interaction between left ventricular ejection
fraction and Killip class
B. Pitt1, F. Zannad2, D.J. Van Veldhuisen3, S. Sutradhar4, J. Vincent4
1University of Michigan Medical Center, Ann Arbor, Mi, United States
of America; 2Inserm, Centre d Investigations Cliniques CI, Nancy,
France; 3University Medical Center Groningen, Groningen,
Netherlands; 4Pfizer Inc, New York, Ny, United States of America
Purpose: The EPHESUS trial demonstrated that aldosterone blockade
with eplerenone significantly decreased risk of all-cause mortality and
CV death in post- AMI patients with HF by 15% (P = 0.008) and 17%
(P = 0.005), respectively. This post hoc analysis of the EPHESUS trial
explored trends in mortality data by baseline LVEF and Killip class.
Methods: 6632 patients with signs and symptoms of CHF post-AMI with
LVSD (EF < 40%) were randomized to receive eplerenone or placebo
plus standard therapy. The trial continued until 1012 deaths occurred
(mean follow-up = 16 months). The primary endpoint was all-cause mor-
tality and the composite of time to CV mortality or CV hospitalization.
Subjects were stratified based on baseline LVEF and Killip class. Cox
regression analyses with treatment (eplerenone vs placebo), Killip class,
and LVEF as explanatory variables in the model, as well as interaction of
Killip class and LVEF were performed.
Results: Risk of all-cause death was 71% higher in subjects with LVEF<
30% vs those with LVEF ≥ 30%. Risk of all cause death was 85% higher
in subjects in Killip Class III/IV vs those in Killip Class I/II. There were
statistically significant interactions between Killip class and LVEF for
all-cause mortality and CV mortality. Cox regression analysis revealed
that mortality risk in patients with Killip class I/II doubled when LVEF
was < 30% vs LVEF ≥ 30% (P < 0.001). However, among patients in
Killip class III/IV mortality risk increased 20% (P = 0.129) when LVEF
was < 30% vs LVEF ≥ 30%.
Summary of all cause death by baseline Killip Class and LVEF
Cox Proportional Hazards Model
Covariate Hazard Ratio 95% CI P value
Killip class III/IV (N = 1298)
vs I/II (N = 5279) 1.851 (1.620, 2.115) <0.001
LVEF <30 (N = 1394)
vs ≥30 (N = 5182) 1.708 (1.495, 1.950) <0.001
Killip I/II LVEF (<30 [N = 1015]
vs ≥30 [N = 263]) 2.043 (1.742, 2.395) <0.001
Killip III/IV LVEF (<30 [N = 379]
vs ≥30 [N = 919]) 1.198 (0.948, 1.514) 0.129
Conclusions: In EPHESUS, Killip class III/IV was associated with
higher mortality than Class I/II, regardless of LVEF. However in Kil-
lip class I/II, those with LVEF < 30% had a significantly higher mor-
tality rate vs those with LVEF ≥ 30%, suggesting the importance of
determining Killip Class and LVEF in these patients.
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Preliminary report on the effects of ultrafiltration in severe heart
failure: the Continuous Ultrafiltration for cOngestive heaRt failurE
(CUORE) trial
M. Muratori1, P.G. Agostoni1, G. Marenzi1, E. Cosentino2,
E. Ferramosca2, G. Forni3, S. Ricci4, F. Pignatti4
1Centro Cardiologico Monzino, Cardiology, Milano, Italy; 2Osp. S.
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Italy
CUORE is an italian multicenter randomized study aimed at analyz-
ing the efficacy of ultrafiltration (UF) vs conventional pharmacological
treatment (Conv) in patients with chronic severe heart failure (HF) who
presented to emergency department for HF worsening and weight gain
>4 kg. Patients will be followed up for 1 year. In case of further acute
decompensation events, patients will be treated again as assigned at the
study enrolment. The present is a preliminary report on the first 21
patients enrolled at December 20, 2007. Ten patients were randomly as-
signed to UF and 11 to Conv. Patients characteristics were: age 73±8 yrs
(UF) and 70±10 yrs (Conv), LVEF 32±7% (UF) and 31±8% (Conv),
BNP 1348±1148 pg/ml (UF) and 1004±623 pg/ml (Conv). Clinical sta-
bilization, defined as absence of clinical signs of fluid retention with oral
treatment since at least 3 days, was reached in 6.3±4.5 days and 9.1±2.3
days in UF and Conv, respectively (p<0.05). At discharge (first hospi-
talization) reduction in body weight was -7.7±4.3 kg (UF) and -7.0±3.5
kg (Conv) (p=NS), serum creatinine changed by -0.2±0.6 mg/dl (UF)
and +0.0±0.3 mg/dl (Conv) (p=NS), BNP by -467±533 pg/ml (UF) and
-428±389 pg/ml (Conv) (p=NS), plasma Na+ by -0.4±2.8 mEq/l (UF)
and +1.6±3.4 mEq/l (Conv) (p=NS). Mean follow up was 141±126 days
(UF) and 190±121 days (Conv). 1 patient died in the UF group and 3 in
the Conv group. Combined events (death and rehospitalization because
of HF) were 4 and 13 in UF and Conv, respectively (p<0.1). This prelim-
inary observation shows that in chronic HF and severe fluid retention UF
allows to reach same body weight and BNP reduction as Conv treatment
with no difference in kidney function. However, clinical stabilization is
reached in a shorter time (as an average 3 days less). Furthermore, the
number of clinical events in the follow-up (death and re-hospitalization
because of worsening HF worsening) shows a positive trend in UF group.
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De novo acute heart failure and acutely decompensated chronic
heart failure: one single syndrome or two different entities?
S. Bugatti, M. Metra, S. Nodari, T. Bordonali, B. Fontanella,
C. Lombardi, P. Milani, G. Verzura, V. Zaca’, L. Dei Cas
Section of Cardiovascular diseases, Experimental and Applied
Medicine, University, Brescia, Italy
Patients (Pts) with acute heart failure (AHF) may present with acutely
decompensated chronic heart failure (ADCHF) or de novo HF. The
differences between these two clinical presentations are not clear. We
have compared clinical characteristics and outcome of ADCHF and de
novo HF in 497 consecutive Pts admitted for AHF.
307 Pts (62%) had ADCHF and 190 (38%) had de novo HF. Compared
to Pts with de novo HF, those with ADCHF were more likely to have
atrial fibrillation (42% vs 27%; p=0.002) and less likely to have a history
of hypertension (47% vs 57%; p=0.03). CAD was present in 59% and
50% of Pts, respectively (p=0.07). Patients with ADCHF also had more
severe symptoms (NYHA class, 3.6±0.5 vs 3.4±0.5 on admission and
2.1±0.7 vs 1.9±0.7 at discharge), lower systolic blood pressure (122±26
vs 132±27 on admission and 109±19 vs 117±18 mmhg at discharge),
higher BUN (79±45 vs 66±40 on admission and 84±46 vs 72±42 gm/l
at discharge) (all p<0.01), lower s-sodium (138±4 vs 139±3 meq/l;
p=0.003), and LVEF (31±13% vs 36±14%; p<0.0001) and were more
likely to have LV dilatation (82% vs 69% of patients; p=0.001) and
medium to severe mitral regurgitation (55% vs 38%; p=0.0003). Length
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